<DOC>
	<DOCNO>NCT00650455</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety , tolerability valdecoxib 10 mg daily ( QD ) naproxen 500 mg twice daily ( BID ) versus placebo , assess efficacy valdecoxib 10 mg QD versus naproxen 500 mg BID , treat sign symptom rheumatoid arthritis ( RA ) severe Rheumatoid Arthritis population .</brief_summary>
	<brief_title>Efficacy Safety Valdecoxib Naproxen Treating Signs Symptoms Rheumatoid Arthritis ( RA ) Severe Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Valdecoxib</mesh_term>
	<criteria>A diagnosis severe rheumatoid arthritis ( RA ) least 6 month The Rheumatoid Arthritis must treat stable regimen include nonsteroidal antiinflammatory drug ( NSAID ) , well methotrexate least 12 week OR NSAID ( least 12 week plus tumor necrosis factor inhibitor ( i.e. , adalimumab [ Humira® ] minimum 5 dos regular schedule , etanercept [ Enbrel® ] 6 week , infliximab ( Remicade® ) 3 dos currently stable regimen infusion every 8 week ) A diagnosis inflammatory arthritis secondary , noninflammatory type arthritis ( eg , osteoarthritis ( OA ) fibromyalgia ) , investigator 's opinion , symptomatic enough interfere evaluation effect valdecoxib patient 's primary diagnosis Rheumatoid Arthritis exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>valdecoxib , severe rheumatoid arthritis</keyword>
</DOC>